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recurrent VTE in any patient. All patients tolerated the anticoagulation regimen. The
mean duration of hospitalization was 334 hours.
Conclusions: In patients with cancer associated DVT, Treatment with NOAC
following PEVI is highly safe and effective. It leads to shorter hospitalization
and no early or late bleeding or recurrent VTE. Patient satisfaction is higher as
the inconveniences associated with long term subcutaneous anticoagulation are
eliminated.Pharmacotherapy - Aspirin, Thienopyridines and other
Platelet Inhibitors
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Background: The incidence of stent thrombosis (ST) after percutaneous coronary
intervention (PCI) is higher among patients with acute coronary syndromes (ACS)
compared with stable ischemic heart disease. Whether this incremental increase in the
risk of ST is constant over the time after PCI is unknown.
Methods: The ADAPT-DES registry prospectively enrolled 8,582 patients with broad
inclusion criteria undergoing successful PCI with drug-eluting stents (DES). All pa-
tients underwent on-treatment platelet function testing using the VerifyNow assay. We
examined adjudicated ST outcomes at prespeciﬁed times following PCI among pa-
tients presenting with ACS with myocardial infarction (MI, n¼2063), ACS with
unstable angina (UA) alone (n¼2370), and no ACS (n¼4149).
Results: Patients with MI had the highest platelet reactivity units (PRU): mean 199
vs. 189 for UA vs. 182 for no ACS (p< 0.0001 for trend); the incidence of high
platelet reactivity deﬁned as PRU>208 was 48.0%, 43.3%, and 39.8%, respectively.
Correspondingly higher rates of 2-year deﬁnite/probable ST were observed among
patients with MI (1.75% vs. 1.13% for UA vs. 0.80% for no ACS, p¼0.003).
However, the increased incremental risk of ST among MI and UA patients was
conﬁned to the early period (ﬁrst 30 days after PCI: 0.98% vs. 0.42% vs. 0.22%,
p¼0.0002). The rates of late and very late ST were not signiﬁcantly different among
the 3 groups (Table).
Conclusions: Among patients undergoing successful DES implantation, the
increased ST risk conferred by the acuity of clinical presentation was conﬁned to
the ﬁrst 30 days after PCI and corresponded with increased on-treatment platelet
reactivity.ACS with
MI
Unstable Angina (ACS
without MI)
No
ACS
p for
trend
Overall ST 1.75% 1.13% 0.80% 0.003
Early ST (0-30
d)
0.98% 0.42% 0.22% <0.001
Late ST (31 d-1
yr)
0.55% 0.48% 0.30% 0.28
Very Late ST
(>1 yr)
0.27% 0.23% 0.31% 0.83
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Prior Clopidogrel Therapy in Patients Presenting with Acute Coronary
Syndromes (ACS) is Associated with Increase Risk of Stent Thrombosis
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Background: Patients sustaining Acute Coronary Syndromes (ACS) despite chronic
aspirin treatment, suffer from worse prognosis as compared to aspirin naïve pa-
tients. Despite growing use of clopidogrel, data regarding the characteristics and
prognostic signiﬁcance of patients with chronic use of clopidogrel sustaining ACS
is limited.
Methods: 5386 consecutive ACS patients who were drawn from the 2008, 2010,
2013 ACS Israeli survey(ACSIS)were characterized and followed-up for 30 days.
For the purpose of this study major adverse cardiac and cerebrovascular event
(MACCE) was deﬁned as death, re-myocardial infarction (MI), stroke and urgent
revascularization.
Results: Out of 5386 patients, 680 (12.6%) were treated with clopidogrel prior to
the index ACS. They were older (6612 vs. 6313 p< 0.01) and suffered more
from diabetes mellitus, hypertension, dyslipidemia as well as prior cardiovascular
history, including prior MI, revascularization, coronary artery bypass graft and
stroke, although, they were less likely to present with ST elevation MI (21% vs.
45%; p < 0.001). Nevertheless, they had more than 2 fold higher incidence of in
hospital stent thrombosis (1.6 % vs. 0.6 %, respectively, p ¼0.006) and stent
thrombosis at 30 days follow-up (2.2% vs. 1.0 %, respectively, p¼0.007). MACCE
rate at 30 days was also higher among chronic clopidogrel treatment patients [15.9
(12.3%) vs. 84 (9.4%), p< 0.01]. Multivariate log regression model analysis showed
that chronic clopidogrel treatment was independent predictors of stent thrombosis
[OR¼2.6 (95%CI 1.2-5.6)].
Conclusions: ACS patients with chronic clopidogrel treatment are at higher risk for in
hospital and 30 days stent thrombosis as well as worse prognosis at 30 days.
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Background: Current guidelines recommend prolonged dual antiplatelet therapy
(DAPT) consisting of aspirin and a thienopyridine for 12 months after drug-eluting
stent implantation. However, prolonged DAPT is associated with bleeding compli-
cations, and patient compliance and cost can be a barrier. Endeavor zotarolimus-
eluting stent (E-ZES) has demonstrated strong safety in short duration DAPT (3
months) analyses but no previous study randomized E-ZES patients to short and
prolonged DAPT.
Methods: Optimized Duration of Clopidogrel Therapy Following Treatment With
the Endeavor Zotarolimus - Eluting Stent in the Real World Clinical Practice
(OPTIMIZE) is an open-label, active-controlled, noninferiority study that random-
ized patients after percutaneous coronary intervention (PCI) 1:1 to 3 or 12 months
of DAPT consisting of aspirin (100-200 mg daily) and clopidogrel (75 mg daily).
Aspirin was prescribed indeﬁnitely. Eligible patients were those with stable coronary
artery disease or history of low-risk acute coronary syndrome undergoing PCI
with E-ZES. A total of 3119 patients in 33 sites in Brazil between April 2010 and
March 2012 were enrolled and randomized to 3 months (n¼ 1563) or 12 months of
DAPT (n¼ 1556). Patients have been followed to 2 years. At 12 months, 3 months
of DAPT was noninferior to 12 months for the composite of death, myocardial
infarction, stroke, or major bleeding, without a signiﬁcant increase in stent
thrombosis.
Results: Two year clinical results will be reported at TCT 2014.
Conclusions: This is the ﬁrst presentation of long-term results in a randomized study
of short (3-month) vs. long-term (12-month) DAPT usage after PCI implantation.rmacotherapy - Aspirin, Thienopyridines and other Platelet Inhibitors B141
